Metronomic capecitabine with hormone therapy after breast cancer
Part of Cancer, Skin clinical trials.
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 70 years old and able to consent to the study
- Your breast cancer is hormone-receptor positive (ER and/or PR positive) and HER2 negative based on pathology results
- You’ve had surgery and chemotherapy, and meet specific post-chemo timing or response criteria
- You must be eligible for hormone therapy (and if you might still have ovaries, you’re considered postmenopausal based on the study rules or blood tests)
- Blood tests and organ function must be strong enough (white blood cells, platelets, hemoglobin, kidney function, and liver enzymes within limits)
- Your health status is good enough (ECOG 0 or 1) and pregnancy test is negative if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This Phase 1b/2 trial tests how safe and how well capecitabine combined with niraparib works for people with HER2-negative, hormone-resistant advanced breast cancer. It may help by slowing tumor growth after standard chemotherapy options have been tried.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.